CN107074801B - 芳基和芳基烷基取代的吡唑基和嘧啶基三环烯酮作为抗氧化炎症调节剂 - Google Patents

芳基和芳基烷基取代的吡唑基和嘧啶基三环烯酮作为抗氧化炎症调节剂 Download PDF

Info

Publication number
CN107074801B
CN107074801B CN201580015069.4A CN201580015069A CN107074801B CN 107074801 B CN107074801 B CN 107074801B CN 201580015069 A CN201580015069 A CN 201580015069A CN 107074801 B CN107074801 B CN 107074801B
Authority
CN
China
Prior art keywords
oxo
phenyl
carbonitrile
methyl
hexahydrobenzo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201580015069.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN107074801A (zh
Inventor
E.安德森
X.蒋
C.本德
G.博尔顿
B.W.卡普拉瑟
C.李
W.罗亚克
P.唐纳
R.瓦纳
J.尚利
H.黑曼
A.克吕格尔
陈慧如
M.罗斯马
D.格拉姆波夫尼克
M.维斯尼克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Reata Pharmaceuticals Inc
Original Assignee
Reata Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Reata Pharmaceuticals Inc filed Critical Reata Pharmaceuticals Inc
Publication of CN107074801A publication Critical patent/CN107074801A/zh
Application granted granted Critical
Publication of CN107074801B publication Critical patent/CN107074801B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72Quinazolines; Hydrogenated quinazolines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN201580015069.4A 2014-01-24 2015-01-23 芳基和芳基烷基取代的吡唑基和嘧啶基三环烯酮作为抗氧化炎症调节剂 Active CN107074801B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461931291P 2014-01-24 2014-01-24
US61/931291 2014-01-24
PCT/US2015/012579 WO2015112792A1 (en) 2014-01-24 2015-01-23 Aryl and arylalkyl substituted pyrazolyl and pyrimidinyl tricyclic enones as antioxidant inflammation modulators

Publications (2)

Publication Number Publication Date
CN107074801A CN107074801A (zh) 2017-08-18
CN107074801B true CN107074801B (zh) 2021-11-05

Family

ID=52484552

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580015069.4A Active CN107074801B (zh) 2014-01-24 2015-01-23 芳基和芳基烷基取代的吡唑基和嘧啶基三环烯酮作为抗氧化炎症调节剂

Country Status (8)

Country Link
US (1) US9464082B2 (enExample)
EP (1) EP3097089B1 (enExample)
JP (1) JP6530758B2 (enExample)
CN (1) CN107074801B (enExample)
CA (1) CA2936550C (enExample)
MX (1) MX372772B (enExample)
TW (1) TWI670263B (enExample)
WO (1) WO2015112792A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2721665C (en) 2008-04-18 2017-01-24 Reata Pharmaceuticals, Inc. Compounds including an anti-inflammatory pharmacore and methods of use
KR101735807B1 (ko) 2008-04-18 2017-05-15 리타 파마슈티컬스 잉크. C-17에 아미노 및 기타 변형을 갖는 올레아놀산 유도체를 포함하는 항산화 염증 조절제
ME02926B (me) 2012-04-27 2018-04-20 Reata Pharmaceuticals Inc 2,2-difluoropropionamidni derivati bardoksolon metila, polimorfni oblici i postupci za njihovu upotrebu
US9512094B2 (en) 2012-09-10 2016-12-06 Reata Pharmaceuticals, Inc. C17-heteroaryl derivatives of oleanolic acid and methods of use thereof
UY39092A (es) 2013-04-24 2021-03-26 Abbvie Inc Derivados de 2,2-difluoropropanamida y metil bardoxolona, formas polimórficas y métodos de uso
US11059792B2 (en) * 2015-02-12 2021-07-13 Reata Pharmaceuticals, Inc. Imidazolyl tricyclic enones as antioxidant inflammation modulators
WO2018095953A1 (de) 2016-11-23 2018-05-31 Bayer Cropscience Aktiengesellschaft 2-[3-(alkylsulfonyl)-2h-indazol-2-yl]-3h-imidazo[4,5-b]pyridin-derivate und ähnliche verbindungen als schädlingsbekämpfungsmittel
TWI831738B (zh) * 2016-12-16 2024-02-11 美商瑞塔醫藥有限責任公司 用於抑制RORγ及其他用途的嘧啶三環烯酮衍生物
BR112020025605A2 (pt) * 2018-06-15 2021-03-23 Reata Pharmaceuticals, Inc. compostos de pirazol e imidazol para inibição de il-17 e rorgama
EP3810141A1 (en) 2018-06-20 2021-04-28 Reata Pharmaceuticals, Inc. Cysteine-dependent inverse agonists of nuclear receptors ror-gamma/ror-gamma-t and methods of treating diseases or disorders therewith
US20250025465A1 (en) * 2021-11-17 2025-01-23 Northwestern University Wt-idh1 inhibition using a covalent and brain-penetrant small molecular inhibitor for ferroptosis induction in high-grade glioma

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012083306A2 (en) * 2010-12-17 2012-06-21 Reata Pharmaceuticals, Inc. Pyrazolyl and pyrimidinyl tricyclic enones as antioxidant inflammation modulators

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1142889A1 (en) * 2000-04-03 2001-10-10 Pfizer Products Inc. Pyrazole derivatives as anti-inflammatory/analgesic agents
EP1438293A2 (en) * 2001-09-19 2004-07-21 Pharmacia Corporation Substituted pyrazolyl benzenesulfamide compounds for the treatment of inflammation
MY163031A (en) 2010-04-12 2017-07-31 Reata Pharmaceuticals Inc Method of treating obesity using antioxidant inflammation modulators

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012083306A2 (en) * 2010-12-17 2012-06-21 Reata Pharmaceuticals, Inc. Pyrazolyl and pyrimidinyl tricyclic enones as antioxidant inflammation modulators

Also Published As

Publication number Publication date
JP2017503840A (ja) 2017-02-02
CA2936550C (en) 2022-07-26
MX2016009589A (es) 2016-10-28
MX372772B (es) 2020-06-29
WO2015112792A1 (en) 2015-07-30
JP6530758B2 (ja) 2019-06-12
US9464082B2 (en) 2016-10-11
TWI670263B (zh) 2019-09-01
CN107074801A (zh) 2017-08-18
EP3097089A1 (en) 2016-11-30
TW201605808A (zh) 2016-02-16
US20150225397A1 (en) 2015-08-13
EP3097089B1 (en) 2021-02-24
CA2936550A1 (en) 2015-07-30

Similar Documents

Publication Publication Date Title
CN107074801B (zh) 芳基和芳基烷基取代的吡唑基和嘧啶基三环烯酮作为抗氧化炎症调节剂
JP6914257B2 (ja) Ror−ガンマのモジュレーター
EP2892910B1 (en) Glycyrrhetinic acid derivatives with anti-inflammatory activity
CA2877550C (en) Imidazopyridine derivatives as modulators of tnf activity
RU2686117C1 (ru) Конденсированные производные имидазола и пиразола в качестве модуляторов активности tnf
CA2663401C (en) Pyrido (2, 3-d) pyrimidinone compounds and their use as pi3 inhibitors
EP3080121B1 (en) Fused tricyclic benzimidazoles derivatives as modulators of tnf activity
US7868024B2 (en) Derivatives of N-(heteroaryl)-1-heteroaryl-1H-indole-2-carboxamides, preparation thereof and therapeutic use thereof
JP7200120B2 (ja) Mk2阻害剤として有用なヘテロアリール化合物
WO2017098328A2 (en) Therapeutic inhibitory compounds
EP3436456B1 (en) Fused hexacyclic imidazole derivatives as modulators of tnf activity
AU2003270783A1 (en) Octahydro-2-H-naphtho[1,2-F] indole-4-carboxamide derivatives as selective glucocorticoid receptor modulators
AU2008226457A1 (en) Aminopyrimidines useful as inhibitors of protein kinases
WO2009026241A1 (en) Heterocyclic modulators of tgr5
AU2004325725A1 (en) Fused bicycloheterocycle substituted quinuclidine derivatives
WO2018170201A1 (en) Deuterated analogs of mk2 inhibitors and uses thereof
JP2023510622A (ja) アザビシクロ置換オキサスピロ環誘導体、その調製方法及び医学的使用
WO2017156177A1 (en) 3-phosphoglycerate dehydrogenase inhibitors and uses thereof
WO2023072026A1 (en) Sarm1 modulators, preparations, and uses thereof
WO2024125624A1 (en) Sarm1 modulators, preparations, and uses thereof
HK40055299A (en) Modulators of ror-gamma
NZ548231A (en) Fused bicycloheterocycle substituted quinuclidine derivatives
HK1161229A (en) Protein kinase inhibitors

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant